There’s good news for approximately 1300 Australians living with cystic fibrosis when it was announced by the PBAC (Pharmaceutical Benefits Advisory Committee) that the potentially life changing drug Orkambi was recommended for listing on the PBS to treat cystic fibrosis patients who are 6 years of age and older.

Orkambi helps reduce the symptoms of CF for those specifically with 2 copies of the DeltaF508 gene.  This is about a third of the CF population in Australia that will benefit.    

Orkambi treats the underlying cause of CF, rather than the symptoms.